Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib

Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib – Case report

Published:2023-12-26 Issue: Volume: Page:
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Barrett Aisling¹^ORCID,Eyre Toby A.¹,Bhuva Shaheel²,Aljurf Mahmoud³,Fakih Riad El³,Ashshi Mohammad A.⁴,Alshaibani Alfadel³

Affiliation:

1. Department of Clinical Haematology Oxford Cancer and Haematology Centre Oxford University Hospitals NHS Foundation Trust Oxford UK

2. Department of Clinical Radiology Oxford University Hospitals NHS Foundation Trust Oxford UK

3. Department of Stem Cell Transplant and Cellular Therapy King Faisal Specialist Hospital and Research Center Riyadh Saudi Arabia

4. College of Medicine Umm Al‐Qura University Makkah Saudi Arabia

Abstract

AbstractCentral nervous system (CNS) involvement by mantle cell lymphoma (MCL) is rare and portends a poor prognosis. We describe the first patient to have a complete response with front‐line treatment with single‐agent acalabrutinib for MCL CNS.

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.830

Reference7 articles.

1. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

2. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

3. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

4. Central nervous system involvement by mantle cell lymphoma;McLaughlin N;Leukemia Lymphoma,2022

5. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse